Hi, I’m
 Dr. Arisha Patel.

Residency training in Internal Medicine.

Fellowship training at an NCI-designated comprehensive cancer center.

Postdoctoral fellowship through the NIH T32 Entrepreneurial Research Training Program. With a cross-disciplinary team of physician-scientists at UPMC and doctoral scientists at Carnegie Mellon, I built machine learning models predicting hospital readmissions in sickle cell disease, published in the British Journal of Haematology, one of the first physician-led applications of machine learning in clinical outcomes research. Alongside my medical training I earned my MBA at Carnegie Mellon’s Tepper School of Business in Biomedical Entrepreneurship and AI in Healthcare.

Senior Medical Director and Medical Director for MyPathway, a tumor-agnostic Phase 2a basket trial spanning molecularly targeted and immuno-oncology therapies. Where novel basket designs did not fit traditional registration pathways, the program’s data supported NCCN Category 2A guideline recommendations, creating evidence-based access to targeted therapies for patients with few remaining options. Additional work included real-world data, machine-learning external control arms, and biomarker-testing coverage and policy.

Adjunct Clinical Instructor in Oncology and Hematology, practicing as a breast oncologist.

BioNurture is a physician-led oncology and hematology practice focused on elevated cancer risk, survivorship, and complex hematologic care.

BioSynova is developing the clinical intelligence and longitudinal data infrastructure behind predictive cancer care.

They merge everything that came before: healthcare outcomes research, clinical trial design, and precision oncology, applied as one framework for cancer prevention and survivorship. The Cancer Resilience Index, a methodology in development, is that framework taking shape.